Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 3/20 | 0.71 |
| ▸ | BLM | P54132 | 5/20 | 0.69 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | RECQL | P46063 | 3/20 | 0.59 |
| ▸ | APEX1 | P27695 | 3/20 | 0.59 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.59 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.59 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7151218 | 1.00 | NFKB1 (0.71) | NFKB1BLMPMP22MAPTTDP1 | |
| Hydrochloric Acid SCHEMBL75743 | 0.98 | BLM (0.72) | NFKB1BLMPMP22MAPTTDP1 | |
| SCHEMBL7149100 | 0.87 | BLM (0.59) | NFKB1BLMPMP22MAPTTDP1 | |
| SCHEMBL7143077 | 0.87 | NFKB1 (0.57) | NFKB1BLMPMP22MAPTTDP1 | |
| SCHEMBL3216247 | 0.86 | NFKB1 (0.66) | NFKB1BLMPMP22MAPTTDP1 | |
| SCHEMBL18652057 | 0.84 | CYP3A4 (0.51) | NFKB1BLMPMP22MAPTCYP3A4 | |
| SCHEMBL18328542 | 0.84 | CYP3A4 (0.51) | NFKB1BLMPMP22MAPTCYP3A4 | |
| Normetanephrine SCHEMBL29516838 | 0.83 | NFKB1 (1.00) | NFKB1BLMPMP22MAPTTDP1 | |
| Normetanephrine SCHEMBL137755 | 0.83 | NFKB1 (1.00) | NFKB1BLMPMP22MAPTTDP1 | |
| Normetanephrine SCHEMBL4949341 | 0.83 | NFKB1 (1.00) | NFKB1BLMPMP22MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1541 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027139-A1 | TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST | VIVUS, INC. | 2026-01-29 | — | — | US | claimed |
| US-20240398729-A1 | Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders | DUKE UNIVERSITY (US) | 2024-12-05 | — | — | US | claimed |
| US-20240225978-A1 | METHODS AND COMPOSITIONS FOR PHARMACOLOGICAL TREATMENT OF BLEPHAROPTOSIS | Bokman, Christine Lynn (US) | 2024-07-11 | — | — | US | claimed |
| US-20240139224-A1 | TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST | AMERICAN ENTERTAINMENT PROPERTIES CORP., AS LENDER | 2024-05-02 | — | — | US | claimed |
| US-20220202750-A1 | DYE COMPOSITION FOR MARKING ORGANIC TISSUE WITH ANAESTHETIC AND METHOD FOR APPLYING SAME | HEXSEL, DORIS MARIA (BR) | 2022-06-30 | — | — | US | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-3840740-A1 | METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION | Maggie's Pearl, LLC (US) | 2021-06-30 | — | — | EP | claimed |
| US-20210161932-A1 | TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST | VIVUS LLC | 2021-06-03 | — | — | US | claimed |
| WO-2020210889-A1 | DYE COMPOSITION FOR MARKING ORGANIC TISSUE WITH ANAESTHETIC AND METHOD FOR APPLYING SAME | HEXSEL, DORIS MARIA (BR) | 2020-10-22 | — | — | WO | claimed |
| EP-3434271-B1 | USE OF PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF POIKILODERMA OF CIVATTE | HEXSEL DORIS MARIA (BR) | 2020-08-26 | — | — | EP | claimed |
| EP-0778768-A4 | FORMULATIONS AND METHODS FOR PROVIDING PROLONGED LOCAL ANESTHESIA | EURO CELTIQUE SA (LU) | 2000-10-11 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5942241-A | A SUSTAINED RELEASE DRUG CONTAINING A SUBSTRATE COMPRISING A LOCAL ANESTHETIC AND A BIOCOMPATIBLE, BIODEGRADABLE, CONTROLLED RELEASE POLYMER SELECTED FROM POLYANHYDRIDES, LACTIC ACID AND GLYCOLIC ACID HOMO-OR/AND COPOLYMERS | EURO-CELTIQUE, S.A. (LU) | 1999-08-24 | — | — | US | claimed |
| US-5922341-A | Local administration of pharmacologically active agents to treat premature ejaculation | VIVUS, INCORPORATED (US) | 1999-07-13 | — | — | US | claimed |
| EP-0852494-A2 | PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-07-15 | — | — | EP | claimed |
| EP-0778768-A1 | FORMULATIONS AND METHODS FOR PROVIDING PROLONGED LOCAL ANESTHESIA | Euroceltique S.A. (LU) | 1997-06-18 | — | — | EP | claimed |
| WO-1997009973-A2 | PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-03-20 | — | — | WO | claimed |
| WO-1996041616-A1 | FORMULATIONS AND METHODS FOR PROVIDING PROLONGED LOCAL ANESTHESIA | EURO-CELTIQUE, S.A. (LU) | 1996-12-27 | — | — | WO | claimed |
| US-4980159-A | EFFECTING RETRACTION OF HAIR; AFTERSHAVING LIQUIDS; DEPILATORIES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1990-12-25 | — | — | US | claimed |
| EP-0152379-A2 | Process for preparing pharmaceutical compositions containing unilamellar liposomes | CIBA-GEIGY AG (CH) | 1985-08-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027139-A1 | TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST | CYP21A2, HSD11B2, CA2 | NFKB1 3526/4885BLM 4698/4885PMP22 3229/4885 |
| US-20210161932-A1 | TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST | CA4, CA9, CA7 | NFKB1 4037/4885BLM 4662/4885PMP22 3326/4885 |
| US-20240139224-A1 | TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST | CA4, CA9, CA7 | NFKB1 4037/4885BLM 4662/4885PMP22 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.